CM
EW icon

Capula Management’s Edwards Lifesciences EW Stock Holding History

Capula Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$192K Buy
+2,400
New +$198K ﹤0.01% 756
2021
Q1 		– Sell
-20,500
Closed -$1.87M – 513
2020
Q4 		$1.87M Buy
+20,500
New +$1.7M 0.09% 177

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Capula Management's EW Position: Q1 2026 in Review

Capula Management opened a new position in Edwards Lifesciences (EW) in Q1 2026: 460 shares worth $36.8K. The stake represents ﹤0.01% of the portfolio and ranks #1017 among its holdings. This is a return to the name: Capula Management previously reported a position in EW as recently as Q4 2022.

Capula Management first reported a position in EW in Q2 2021 and has held it in 5 quarters since. The position peaked at $964K in Q4 2022. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Capula Management held 460 shares of Edwards Lifesciences worth $36.8K as of Q1 2026.
  • Edwards Lifesciences was a new Capula Management position in Q1 2026.
  • Edwards Lifesciences made up ﹤0.01% of Capula Management's portfolio in Q1 2026, its #1017 holding.
  • Capula Management first reported a position in Edwards Lifesciences in Q2 2021 and has held it in 5 quarters since.
  • Capula Management's Edwards Lifesciences position peaked at $964K in Q4 2022.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Capula Management's 13F filing for Q1 2026, filed 14 May 2026.